文献速递消化道肿瘤放疗

NRG-GI007:OBP-301联合根治性放化疗治疗局部晚期食管癌的Ⅰ期研究

NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2026-06-11

该Ⅰ期研究在15例局部晚期食管癌患者中评估瘤内注射OBP-301联合卡铂/紫杉醇及50.4 Gy放疗的安全性,未观察到剂量限制性毒性,可评估患者临床完全缓解率为100%(95% CI 77-100),1年总生存率60%,无进展生存率53%。

要点

  • OBP-301联合放化疗未出现剂量限制性毒性,最常见3/4级毒性为中性粒细胞减少(40%)和淋巴细胞减少(33%)。
  • 再分期患者(n=13)临床完全缓解率达100%(95% CI 77-100),全部15例为87%(95% CI 62-96)。
  • 1年时9例(60%)存活,8例(53%)无进展存活。

核心结论

  • OBP-301在放化疗前及期间给药可行且安全,临床完全缓解率很有前景,随机研究正在计划中。

研究设计与样本

  • Ⅰ期研究,2020年6月至2024年7月入组15例可评估的局部晚期食管癌患者。
  • 患者接受卡铂/紫杉醇联合50.4 Gy放疗,并于放疗前3天及放疗第12、26天经内镜瘤内注射OBP-301。
  • 主要终点为方案定义的剂量限制性毒性,次要终点包括临床完全缓解率、1年总生存和无进展生存。

主要发现

  • 未观察到剂量限制性毒性;最常见治疗相关3/4级毒性为中性粒细胞减少(40%)和淋巴细胞减少(33%)。
  • 2例在再分期前死亡:1例在放化疗后6周发生5级呼吸衰竭(疑似放射性肺炎),另1例基线有未识别的气道受累导致放化疗第3周发生气管食管瘘。
  • 再分期患者(n=13)临床完全缓解率为100%(95% CI 77-100),全部15例为87%(95% CI 62-96)。
  • 1年时15例中9例(60%)存活,8例(53%)无进展存活。

关键数值与推荐

  • 主要终点剂量限制性毒性:未观察到。
  • 临床完全缓解率:再分期患者(n=13)100%(95% CI 77-100);全部15例87%(95% CI 62-96)。
  • 1年总生存:9/15(60%);1年无进展生存:8/15(53%)。
  • 放疗剂量:50.4 Gy;OBP-301给药时间:放疗前3天及放疗第12、26天。

临床怎么用

  • 对于医学上无法手术的局部晚期食管癌,OBP-301联合卡铂/紫杉醇及50.4 Gy放疗显示出可行性和安全性。
  • 治疗前需仔细评估气道受累情况,以避免气管食管瘘等严重并发症。
  • 该联合方案的临床完全缓解率数据支持进一步开展随机研究验证。

局限性

  • Ⅰ期研究样本量小(15例可评估),结果需更大样本验证。
  • 2例在再分期前死亡,可能影响疗效评估。
  • 随访时间有限,1年生存数据尚不成熟。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Definitive chemoradiation (CRT) is standard for patients with medically inoperable esophageal cancer. OBP-301 is a modified adenovirus that adds a human telomerase reverse transcriptase gene promoter, replicating only in tumor cells to cause lysis. METHODS AND MATERIALS: In this phase 1 study, OBP-301 was added to carboplatin/paclitaxel and radiation therapy (RT) (50.4 Gy). Patients received intratumoral OBP-301 via endoscopy 3 days prior to and then at days 12 and 26 of RT. The primary endpoint was protocol-defined dose-limiting toxicity. Secondary endpoints included clinical complete response (cCR) rate, number alive and alive without progression at 1 year. RESULTS: From June 2020 to July 2024, 15 evaluable patients were enrolled. Fourteen patients (93%) received all planned OBP-301 injections and 50.4 Gy RT. No dose-limiting toxicities were observed. The most common treatment-related grade 3/4 toxicities were neutropenia (40%) and lymphopenia (33%). Two patients died prior to restaging: 1 patient developed grade 5 respiratory failure 6 weeks after CRT (suspected RT pneumonitis), whereas a second patient had unrecognized airway involvement at baseline, which led to a tracheoesophageal fistula during Week 3 of CRT. The cCR rate for patients undergoing restaging (n = 13) was 100% (95% CI, 77-100), and 87% (95% CI, 62-96) for all 15 patients. At 1 year, 9 (60%) out of 15 patients are still alive and 8 (53%) are alive without progression. CONCLUSIONS: OBP-301 administration before and during CRT is feasible and safe, resulting in a very promising cCR rate. A randomized study is being planned to further evaluate safety and efficacy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ku GY, Winter K, Ilson D, et al. NRG-GI007: Phase 1 Study of OBP-301, An Oncolytic Virus, and Definitive Chemoradiation in Locally Advanced Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 42269787. doi:10.1016/j.ijrobp.2026.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。